Notice on Further Advancing Policy Interpretation for the Alignment and Implementation of the Medical Service Price Project Establishment Guidelines

People's Republic of China – National Healthcare Security

Main information

Scope of Application:

Provincial/municipal healthcare security authorities, medical institutions, medical device, reagent and pharmaceutical enterprises across China

Effective Date:

July 21, 2026

Related Provisions:

- National Medical-Service-Price Project Establishment Guidelines
- Measures for the Administration of Medical Service Prices
- Local medical service price mapping and implementation documents

Pharm.east

Key Topics

Framework

- **The notice sets up a multi-level interpretation work system covering national guidance, provincial implementation and hospital-level on-site execution for rolling-out the price-establishment guidelines.**
- **It defines core work modules including unified interpretation caliber, layered training, public Q&A mechanism and supervision of local implementation quality.**

What's new

- **It mandates standardized local policy interpretation to eliminate inconsistent understandings of project mapping, surcharge items and expanded items across different provinces.**
- **It requires provinces to compile unified training materials and public FAQ documents to bridge gaps between national guidelines and locally-adopted price rules.**

Sensitive Factors

- **Misinterpretation of mapping relationships between old and new price projects may trigger non-compliant billing risks for hospitals and cost fluctuations for patients.**
- **Imbalanced local implementation progress may create cross-province discrepancies in price item definitions and commercial product reimbursement-related conditions.**

HealthLawAsia – Zunarelli Group – All Rights Reserved

Drivers

- **Regulatory compliance risk prevention: Companies must update product-related documentation and customer-support materials to match newly-unified medical-service-price definitions to avoid billing-related regulatory penalties.**
- **Commercial and tender-readiness requirements: Enterprises need to align device/reagent business models with revised local price-mapping rules to maintain eligibility for hospital procurement and clinical adoption.**
- **Stakeholder communication necessity: Businesses should keep track of provincial interpretation documents to respond timely to clinical-sector questions about how their products fit into new price-project frameworks.**